Novartis announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, which overshadowed a modest outlook raise. Novartis CEO Vasant Narasimham speaks with Bloomberg's Scarlet Fu on the impact of pharma tariffs.

Charles Schwab CEO Rick Wurster Talks SpaceX, Future Big IPOs
07:54

Former Fed Vice Chair Lael Brainard Talks Warsh's First Fed Meeting
11:31

Yardeni Research President Ed Yardeni Talks State of the Market
06:59